drugset / Trial / NCT01937364

Preventing Alcohol Withdrawal With Oral Baclofen

NCT01937364

Phase 2 Terminated 17 enrolled Essentia Health
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is determine if the medication baclofen can prevent the symptoms of Alcohol Withdrawal Syndrome (AWS) in hospitalized patients who may be at risk for AWS. This medication is most often used for patients who have spasticity of their muscles due to a neuromuscular disease. In several European studies, and in an earlier study at Essentia Health (NCT00597701), baclofen has been found to have a significant effect on the severity of symptoms of AWS.

Timeline

Start
2013-11
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Baclofen Small molecule 10 mg